Organogenesis
Canton
About Organogenesis
Organogenesis Inc. is a regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell based product (Apligraf®, approved for the treatment of venous leg ulcers). Apligraf is now the leading regenerative medicine product in the world, with two FDA-approved indications. In 2012 we received an FDA approval for GINTUIT™, a living, human cell-based product that represents a new therapeutic class in dentistry.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $614.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2024)
- Ticker: nasdaq:ORGO
- Website: organogenesis.com
- Phone: +117815750775
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/organogenesis-89743 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.